10505
|
ETCTN
|
A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10507
|
ETCTN
|
A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10508
|
ETCTN
|
A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10509
|
ETCTN
|
A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10512
|
ETCTN
|
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10517
|
ETCTN
|
An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib with or without Atezolizumab in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (NERA)
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10522
|
ETCTN
|
A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10525
|
ETCTN
|
A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10527
|
ETCTN
|
A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|
10528
|
ETCTN
|
A Phase 1 Study of the Polymerase Theta (POLθ) Inhibitor Novobiocin in BRCA-mutant and Other DNA Damage Repair-Deficient Solid Tumors
|
Adult CIRB - Early Phase Emphasis
|
Available to Open
|
|